Overview
IgA nephropathy (Berger disease) is a kidney disease caused by deposits of immunoglobulin A (IgA) in the glomeruli. It is the most common primary glomerulonephritis worldwide and can lead to end-stage renal disease in 20-40% of patients over 20 years.
Sporadic/Multifactorial
Childhood to adulthood
Can begin any time from childhood through adulthood
FDA & Trial Timeline
10 eventsNovartis Pharmaceuticals
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. — PHASE2
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology — EARLY_PHASE1
Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd. — PHASE1
Novartis Pharmaceuticals — PHASE2
Purespring Therapeutics Limited — PHASE1, PHASE2
Guangdong Hengrui Pharmaceutical Co., Ltd — PHASE2
Haisco Pharmaceutical Group Co., Ltd. — PHASE3
University of California, Los Angeles — NA
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
5 availableVoyxact
Voyxact (sibeprenlimab) is a first-in-class APRIL inhibitor approved for reduction of proteinuria in adults with primary IgA nephropathy at risk for disease progression. It achieved a 51% placebo-adju…
Voyxact (sibeprenlimab) is a first-in-class APRIL inhibitor approved for reduction of proteinuria in adults with primary IgA nephropathy at risk for disease progression. It achieved a 51% placebo-adjusted reduction in proteinuria in the Phase 3 VISIONARY trial.
Vanrafia
Vanrafia (atrasentan) is the first and only selective endothelin A receptor antagonist approved for reduction of proteinuria in adults with primary IgA nephropathy at risk of rapid disease progression…
Vanrafia (atrasentan) is the first and only selective endothelin A receptor antagonist approved for reduction of proteinuria in adults with primary IgA nephropathy at risk of rapid disease progression. FDA accelerated approval based on Phase 3 ALIGN trial.
FABHALTA
the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥ 1.5 g/g
Filspari
Indicated to reduce proteinuria in adults with primary IgA nephropathy at risk of rapid disease progression.
Tarpeyo
Indicated to reduce proteinuria in adults with primary IgA nephropathy at risk of rapid disease progression.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Financial Resources
5 resourcesTravel Grants
No travel grants are currently matched to IgA Nephropathy.
Community
No community posts yet. Be the first to share your experience with IgA Nephropathy.
Start the conversation →Latest news about IgA Nephropathy
5 articlesCaregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about IgA Nephropathy
What is IgA Nephropathy?
IgA nephropathy (Berger disease) is a kidney disease caused by deposits of immunoglobulin A (IgA) in the glomeruli. It is the most common primary glomerulonephritis worldwide and can lead to end-stage renal disease in 20-40% of patients over 20 years.
How is IgA Nephropathy inherited?
IgA Nephropathy follows a sporadic/multifactorial inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does IgA Nephropathy typically begin?
Typical onset of IgA Nephropathy is childhood to adulthood. Age of onset can vary across affected individuals.
Are there clinical trials for IgA Nephropathy?
Yes — 20 recruiting clinical trials are currently listed for IgA Nephropathy on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.
Which specialists treat IgA Nephropathy?
25 specialists and care centers treating IgA Nephropathy are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.
What treatment and support options exist for IgA Nephropathy?
5 patient support programs are currently tracked on UniteRare for IgA Nephropathy. See the treatments and support programs sections for copay assistance, eligibility, and contact details.